Citalopram-induced Raynaud’s phenomenon

Selective serotonin reuptake inhibitors (SSRIs) are being proposed for inhibiting vasoconstriction in Raynaud’s phenomenon-patients (RP) [1–3]. Recently, Herrick revised vascular, neural and intravascular abnormalities which may have a pathophysiological role in RP. It is well known that endothelial cells and platelets activation -mediate by circulating factors as tromboxane A2 and serotonin (5-HT)control vascular tone and governs several functions involving the vessel wall and the interstitial zone. Repeated attacks of vasospasm may cause ischaemic reperfusion injury to the endothelium, resulting in a vicious and self propagating cycle of cause [2]. But the mechanism of SSRIs real clinical beneWt is not completely understood because serotonin has the ability to also stimulate vasodilatation in healthy vascular bed [4]. Here we report the Wrst case of RP associated with citalopram administration. Case report